Last10K.com

Glycomimetics Inc (GLYC) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Glycomimetics Inc

CIK: 1253689 Ticker: GLYC

EXHIBIT 99.1

Picture 1

 

 

GLYCOMIMETICS REPORTS 

FOURTH QUARTER AND YEAR-END 2017 RESULTS 

 

·

In an oral presentation of data from its Phase 1/2 AML trial of GMI-1271 at the American Society of Hematology Annual Meeting (ASH), GlycoMimetics reported:

o

Improvements in median overall survival compared to historical matched controls for two AML patient populations

o

Improvements in other clinical outcomes, including durability of remission in high-risk patients plus safety and tolerability data, including low mucositis rates

·

In a second oral presentation at the ASH meeting, GlycoMimetics highlighted the underlying, differentiated mechanism of action for GMI-1271, including its ability to enhance sensitivity to chemotherapy. 

·

The Phase 3 trial of rivipansel remains on track for completion during the second half of 2018.

·

GlycoMimetics was included in the Nasdaq Biotechnology Index® (NBI), effective Monday, December 18, 2017.

·

Conference call scheduled for 8:30 a.m. this morning, dial-in and webcast details below.

 

ROCKVILLE, MD, MARCH 6, 2018

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2017.

“Highlighting the fourth quarter of 2017, GlycoMimetics presented a robust data set for its Phase 1/2 study of GMI-1271 for the treatment of AML patients. This data provided the basis for discussions with the U.S. FDA focused on a Phase 3 trial design – the result of which we announced yesterday. The ongoing discussions were made possible via our Breakthrough Therapy designation for GMI-1271 for the treatment of relapsed/refractory AML patients, and we now plan to initiate our own Phase 3 trial in this patient population later this year,” noted Rachel King, Chief Executive Officer.

Recent Operational Highlights:

·

In the Phase 1/2 clinical trial, acute myeloid leukemia (AML) patients treated with GMI-1271, a specific E-selectin inhibitor, together with standard chemotherapy, consistently performed better


The following information was filed by Glycomimetics Inc (GLYC) on Tuesday, March 6, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Glycomimetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Glycomimetics Inc.

Continue

Assess how Glycomimetics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (tables)
Accrued Expenses - Summary Of Accrued Expenses (detail)
Description Of The Business
Description Of The Business - Additional Information (detail)
Employee Benefit Plan
Employee Benefit Plan (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Nols And Carryforwards (detail)
Income Taxes - Reconciliation Between Statutory Federal Income Tax Rate And Effective Income Tax Rate (detail)
Income Taxes - Schedule Of Gross Deferred Tax Asset And Related Valuation Allowance (detail)
Income Taxes - Tax Cuts And Jobs Act (details)
Net (loss) Income Per Share Of Common Stock (detail)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (tables)
Operating Leases
Operating Leases (details)
Operating Leases (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (tables)
Prepaid Expenses And Other Current Assets - Summary Of Prepaid Expenses And Other Current Assets (detail)
Property And Equipment
Property And Equipment (detail)
Property And Equipment (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (detail)
Quarterly Financial Information (unaudited) (tables)
Research And License Agreements
Research And License Agreements - Additional Information (detail)
Significant Accounting Policies - Recently Issued Accounting Standards (detail)
Stockholders Equity (tables)
Stockholders' Equity
Stockholders' Equity - Common Stock Warrants (detail)
Stockholders' Equity - Company's Stock Option Activity (detail)
Stockholders' Equity - Equity Offerings (detail)
Stockholders' Equity - Incentive Plans (detail)
Stockholders' Equity - Stock-based Compensation Expense (detail)
Stockholders' Equity - Summary Of Rsu Activity (detail)
Stockholders' Equity - Weighted-average Assumptions (detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (detail)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Property And Equipment (detail)

Material Contracts, Statements, Certifications & more

Glycomimetics Inc provided additional information to their SEC Filing as exhibits

Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-18-001553
Submitted to the SEC: Tue Mar 06 2018 4:02:21 PM EST
Accepted by the SEC: Tue Mar 06 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/glyc/0001558370-18-001553.htm